BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/12/2017 6:39:43 AM | Browse: 353 | Download: 143
Publication Name World Journal of Gastroenterology
Manuscript ID 34971
Country/Territory Iran
2017-06-07 00:39
Peer-Review Started
2017-06-08 01:08
To Make the First Decision
2017-07-13 05:02
Return for Revision
2017-07-17 11:55
2017-09-14 03:49
Second Decision
2017-09-15 00:07
Accepted by Journal Editor-in-Chief
2017-09-16 02:36
Accepted by Company Editor-in-Chief
2017-09-19 21:01
Articles in Press
2017-09-19 21:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
2017-10-30 20:59
Typeset the Manuscript
2017-11-06 04:41
Publish the Manuscript Online
2017-11-12 06:39
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Editorial
Article Title Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
Manuscript Source Invited Manuscript
All Author List Ahad Eshraghian
Author(s) ORCID Number
Ahad Eshraghian http://orcid.org/0000-0003-0751-5712
Funding Agency and Grant Number
Corresponding author Ahad Eshraghian, MD, Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz 71937-11351, Iran. eshraghiana@yahoo.com
Keywords Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Vitamin E; Pioglitazone; Pharmacological therapy; Obeticholic acid
Core Tip Non- alcoholic fatty liver disease (NAFLD) is an increasing liver disease worldwide. However, most of patients are treated with life style modification including weight loss and dietary regimen. Pharmacologic therapy may be indicated in a group of patients with non-alcoholic steatohepatitis. Here in, the current and emerging medications for treatment of NAFLD was reviewed briefly with regard of their beneficial effects on histological outcomes.
Publish Date 2017-11-12 06:39
Citation Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(42): 7495-7504
Url http://www.wjgnet.com/1007-9327/full/v23/i42/7495.htm
DOI http://dx.doi.org/10.3748/wjg.v23.i42.7495
Full Article (PDF) WJG-23-7495.pdf
Full Article (Word) WJG-23-7495.doc
Manuscript File 34971-Review.docx
Answering Reviewers 34971-Answering reviewers.pdf
Audio Core Tip 34971-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 34971-Conflict-of-interest statement.pdf
Copyright License Agreement 34971-Copyright assignment.pdf
Peer-review Report 34971-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 34971-Journal editor-in-chief review report.pdf
Scientific Misconduct Check 34971-Scientific misconduct check.pdf
Scientific Editor Work List 34971-Scientific editor work list.pdf